Keeping Drugs Out of Synapses

  • Author: ChemistryViews.org
  • Published: 14 August 2016
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Nano Letters/ACS Publications
  • Associated Societies: American Chemical Society (ACS), USA
thumbnail image: Keeping Drugs Out of Synapses

N-methyl-D-aspartate (NMDA) receptors in the brain are important for learning and memory, and their overactivation plays a role in diseases, e.g., Alzheimer's and Huntington's disease. However, antagonists that block these receptors can have serious side effects such as hallucinations. NDMA receptors are found in different locations: inside synapses, where they are important for normal function, and outside of synapses, where their activation plays a part in pathological processes. Until now, antagonists cannot discriminate between NMDA receptor activity in synapses and outside of synapses.


Elena Molokanova, Nanotools Bioscience, Encinitas, CA, USA, and colleagues have developed an NMDA receptor antagonist that is simply too large to fit in the synaptic cleft and thus inhibits only extrasynaptic receptors. The synaptic cleft has an average size of 25 nm, and the team built a nanostructure with a diameter of roughly 35 nm. The hybrid drug consists of a gold nanoparticle core, a polymer linker, and memantine, an NMDA receptor antagonist. The compound contains about 50 molecules of memantine per nanoparticle.


The researchers tested the effects of the drug in vitro and found that it effectively inhibited extrasynaptic NMDA receptors, but had no influence on synaptic activity. Further studies showed that the hybrid drug can successfully penetrate brain tissue. The team hopes that further development of such rationally designed antagonists might result in new neuroprotective drugs. The drug design strategy could also be extended to other nanoparticle cores and active molecules.


 

Article Views: 1650

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


Magazine of Chemistry Europe (16 European Chemical Societies)published by Wiley-VCH